Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
109,272,143
-
Total 13F shares
-
1,187,087
-
Share change
-
+217,746
-
Total reported value
-
$1,652,710
-
Price per share
-
$1.40
-
Number of holders
-
34
-
Value change
-
+$287,570
-
Number of buys
-
16
-
Number of sells
-
8
Institutional Holders of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) as of Q4 2021
As of 31 Dec 2021,
ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,187,087 shares.
The largest 10 holders included
RENAISSANCE TECHNOLOGIES LLC, INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC, Advisor Resource Council, CITADEL ADVISORS LLC, MORGAN STANLEY, CIBC World Markets Inc., TWO SIGMA ADVISERS, LP, ROYAL BANK OF CANADA, Long Focus Capital Management, LLC, and JPMORGAN CHASE & CO.
This page lists
34
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.